Great organizations thrive by looking forward, and the National Lipid Association is no different.
In looking forward, we must have a vision of how we will continue to grow our brand and membership, which ultimately helps advance the practice of clinical lipidology. NLA leadership, along with some special invited guests, met in Orlando for a Strategic Planning session in January to define exactly what that vision looks like.
Article By:
JAMES A. UNDERBERG, MD, MS, FNLA
President, National Lipid Association
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for
Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic New York, NY
Diplomate, American Board of Clinical Lipidology
Last Updated: Monday, 29-Jan-2018 21:45:00 EST
JACKSONVILLE, Fla. -- The National Lipid Association announced Monday it has united with MD Magazine®, a leading online and print source of physician news, conference coverage, and peer-to-peer discussion, through Michael J. Hennessy Associates' Strategic Alliance Partnership (SAP) Program. The partnership will also include sister publications, Rare Disease Report® and Pharmacy Times®.
The National Lipid Association will be accepting submissions for the Junior Faculty Research Award from November 1, 2017 to January 31, 2018. The purpose of this award is to encourage the scholarly advancement of Junior Faculty members at nonprofit institutions as they pursue developments in hyperlipidemia and other lipid disorders in humans.
This page was last updated: Nov 07, 2018
The National Lipid Association announced on Wednesday its support of the Lipoprotein(a) Foundation’s efforts to promote a new ICD-10 Diagnostic-Code for high Lp(a).
This page was last updated: Nov 07, 2018
Last Updated: Wednesday, 11-Oct-2017 18:45:00 EDT
The National Lipid Association announced on Wednesday its support of the Lipoprotein(a) Foundation’s efforts to promote a new ICD-10 Diagnostic-Code for high Lp(a).
The NLA believes the new code will be beneficial in identifying lethal risk factors in patients. To further support this initiative, NLA members are encouraged to email the ICD-10 Coordination and Maintenance Committee before November 13, 2017.
Last Updated: Tuesday, 29-Aug-2017 17:15:00 EDT
The National Lipid Association (NLA) welcomes the results of the REVEAL trial which demonstrated that reductions in cholesterol levels with anacetrapib were associated with a reduction in cardiovascular events. Specifically, cholesterol drug anacetrapib produced reductions in low density lipoprotein (LDL) cholesterol levels, non-high density lipoprotein (non-HDL) cholesterol levels, lipoprotein(a) levels and a profound increase in high density lipoprotein (HDL) cholesterol levels. These favorable lipid changes were associated with a significant reduction in cardiovascular events
The National Lipid Association and the Foundation are thankful once again for another successful year of meetings and fundraising. But we still have much work to do.
Article By:
ANNE C. GOLDBERG, MD, FNLA
President, Foundation of the National Lipid Association
Associate Professor of Medicine Washington University School of Medicine
St. Louis, MO
Diplomate, American Board of Clinical Lipidology
Last Updated: Friday, 18-Aug-2017 18:30:00 EDT
The American Board of Clinical Lipidology (ABCL) Board of Directors has published a list of recommended reading for those preparing for maintenance of certification (MOC). If you’re studying for the exam, you can find a list of suggested reading at lipidboard.org/moc.
The American Board of Clinical Lipidology (ABCL) Board of Directors has published a list of recommended reading for those preparing for maintenance of certification (MOC). If you’re studying for the exam, you can find a list of suggested reading at lipidboard.org/moc.
This page was last updated: Aug 18, 2017